Revenue
1.49 million USD
2026 Q3 · USD
Exact inputs and evidence
- Revenue: 1493788 USD Source
Fundies. English
Citius Pharmaceuticals, Inc.
EDGAR84 filing records in this dataset, filed from 2010-11-23 to 2026-10-26. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-785.39%
2026 Q3 · %
Operating cash flow
-8.69 million USD
2026 Q3 · USD
- Cash and cash equivalents
- 17 million USD Source
Exact value
17000000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 27.5 million shares Source
Exact value
27452570 shares
Reported share-count change
89.65% · 13 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-34.9 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -26552738 USD · 2024-10-01 – 2025-09-30 Source
- Operating cash flow: -14671948 USD · 2024-10-01 – 2025-06-30 Source
- Operating cash flow: -13008822 USD · 2025-10-01 – 2025-12-31 Source
- Operating cash flow: -14308843 USD · 2025-10-01 – 2026-03-31 Source
- Operating cash flow: -13008822 USD · 2025-10-01 – 2025-12-31 Source
- Operating cash flow: -23000000 USD · 2025-10-01 – 2026-06-30 Source
- Operating cash flow: -14308843 USD · 2025-10-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-26.
Financial data available through: 2025-09-30.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 11 of 11 periods available· newest 2025-09-30
- Net income: 9 of 11 periods available· newest 2023-09-30
- Operating cash flow: 11 of 11 periods available· newest 2025-09-30
- Capital expenditure: 3 of 11 periods available· newest 2021-09-30
- Total assets: 11 of 11 periods available· newest 2025-09-30
- Total liabilities: 7 of 11 periods available· newest 2025-09-30
- Current assets: 11 of 11 periods available· newest 2025-09-30
- Current liabilities: 11 of 11 periods available· newest 2025-09-30
- Cash and cash equivalents: 11 of 11 periods available· newest 2025-09-30
- long term debt: No compatible figures in this window
- Shares outstanding: 11 of 11 periods available· newest 2025-09-30
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Operating cash flow
+USD 1.65 millionPrior period
−USD 28.2 million
–
Current period
−USD 26.55 million
–
Exact inputs and evidence
-26552738 − -28201375 = 1648637 USD
-28201375 USD · 2023-10-01 – 2024-09-30
Inspect prior input Prior source-26552738 USD · 2024-10-01 – 2025-09-30
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Net income, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2015-10-01 – 2016-09-30 | −USD 8.3 million Exact valueExact value: -8295698 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.9 million Exact valueExact value: -5900421 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2016-10-01 – 2017-09-30 | −USD 10.38 million Exact valueExact value: -10384953 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.97 million Exact valueExact value: -7971205 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2,126 Exact valueExact value: 2126 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.97 million Calculation and evidence-7971205 − 2126 USD Exact free cash flow: -7973331 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2017-10-01 – 2018-09-30 | −USD 12.54 million Exact valueExact value: -12536638 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 11.32 million Exact valueExact value: -11318138 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2018-10-01 – 2019-09-30 | −USD 15.56 million Exact valueExact value: -15562144 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.44 million Exact valueExact value: -12437751 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2019-10-01 – 2020-09-30 | −USD 17.55 million Exact valueExact value: -17548085 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.93 million Exact valueExact value: -16930658 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1,831 Exact valueExact value: 1831 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.93 million Calculation and evidence-16930658 − 1831 USD Exact free cash flow: -16932489 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2020-10-01 – 2021-09-30 | −USD 23.05 million Exact valueExact value: -23054434 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.25 million Exact valueExact value: -24250414 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 6,938 Exact valueExact value: 6938 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.26 million Calculation and evidence-24250414 − 6938 USD Exact free cash flow: -24257352 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2021-10-01 – 2022-09-30 | −USD 33.64 million Exact valueExact value: -33640646 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 28.36 million Exact valueExact value: -28361256 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2022-10-01 – 2023-09-30 | −USD 32.54 million Exact valueExact value: -32542912 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 29.06 million Exact valueExact value: -29060212 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2023-10-01 – 2024-09-30 | Unavailable Not reported for this period. | −USD 28.2 million Exact valueExact value: -28201375 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2024-10-01 – 2025-09-30 | Unavailable Not reported for this period. | −USD 26.55 million Exact valueExact value: -26552738 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
84 filings · 3,336 latest values · 3,334 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001506251, 1506251, CTXR, edgar:1506251
Also known as CITIUS PHARMACEUTICALS, INC., Citius Pharmaceuticals, Inc., Trail One, Inc., TrailOne, Inc.